BML Capital Management LLC Trims Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

BML Capital Management LLC cut its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 42.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 228,500 shares of the biopharmaceutical company’s stock after selling 169,780 shares during the period. Vanda Pharmaceuticals comprises approximately 0.6% of BML Capital Management LLC’s portfolio, making the stock its 19th largest position. BML Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $1,072,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sei Investments Co. raised its holdings in shares of Vanda Pharmaceuticals by 39.6% in the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 147,066 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at about $1,158,000. Acadian Asset Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 4.7% in the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after buying an additional 107,203 shares during the last quarter. Monaco Asset Management SAM purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $1,090,000. Finally, Empowered Funds LLC raised its holdings in shares of Vanda Pharmaceuticals by 8.2% in the first quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock valued at $827,000 after buying an additional 15,215 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VNDA has been the subject of a number of research reports. HC Wainwright initiated coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a “buy” rating and a $18.00 target price for the company. Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a report on Saturday. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Stock Up 2.2 %

NASDAQ VNDA traded up $0.12 during trading hours on Tuesday, hitting $5.46. 204,424 shares of the stock were exchanged, compared to its average volume of 1,302,546. The company has a market cap of $318.26 million, a price-to-earnings ratio of -19.07 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 12-month low of $3.32 and a 12-month high of $6.75. The stock has a 50-day moving average of $4.79 and a 200 day moving average of $5.25.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.